Correction: Zhao et al. Artesunate Inhibits Metastatic Potential in Cisplatin-Resistant Bladder Cancer Cells by Altering Integrins. Cells 2025, 14, 570

To better reflect the first two authors’ contributions in the original article [1], the authorship order has been revised, and the following back matter statements have been updated:

Author Contributions

Conceptualization, E.J.; data curation, F.Z., O.V. and I.T.; formal analysis, F.Z.; funding acquisition, J.C.J., M.M. and E.J.; investigation, E.J.; methodology, F.Z., S.D.M., K.S.S., M.P.B., J.C.J. and M.M.; project administration, E.J.; resources, J.C.J., M.M., T.E. and E.J.; software, F.Z.; supervision, E.J.; validation, O.V.; visualization, F.Z. and O.V.; writing—original draft, F.Z., O.V. and E.J.; writing—review and editing, T.E., R.A.B., A.H. and E.J. R.A.B. is an expert on integrins and therefore had a closer look at the data. He gave several impulses for data presentation and the discussion part. A.H. reviewed the manuscript with his huge expertise regarding urologic cancers and the challenge of treating them in the metastatic stage. He had a great impact on the structure and therewith the end version of the manuscript. All authors have read and agreed to the published version of the manuscript.

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors on request. All data are from F.Z.’s Ph.D. thesis, which is archived in the library of the Johannes Gutenberg University Mainz.

These corrections are solely administrative in nature and concern authorship, attribution, and transparency regarding the origin of the data. The updates do not affect the scientific content, methodology, results, interpretation, or conclusions of the article. Accordingly, the validity, integrity, and reliability of the reported findings remain fully unchanged.